{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:14:58Z","timestamp":1780607698440,"version":"3.54.1"},"reference-count":33,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Multicenter Networks for Ideal Outcomes of Pediatric Rare Endocrine and Metabolic Disease in Korea (OUTSPREAD Study)","award":["5-2022-D0737-00007"],"award-info":[{"award-number":["5-2022-D0737-00007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>We conducted a retrospective study on 51 pediatric patients with newly diagnosed chronic myeloid leukemia chronic phase or accelerated phase. The patients were classified into the IMA group (N = 33), treated with imatinib, and the DSA group (N = 18), treated with dasatinib, as front-line tyrosine kinase inhibitors (TKIs). At 12 months, the rates of complete cytogenetic response were similar between the IMA group (92.3%) and DSA group (100%) (p = 0.305). However, the rate of early molecular response was higher in the DSA group than in the IMA group (100.0% vs. 80.0%, p = 0.043). By 12 and 24 months, the DSA group showed faster and higher cumulative rates of both major (DSA group: 72.2% and 100%, respectively; IMA group: 41.2% and 68.7%, respectively; p = 0.002) and deep molecular responses (DSA group: 26.0% and 43.6%, respectively; IMA group: 13.8% and 17.5%, respectively; p = 0.004). Both TKIs were well tolerated. Although the height standard deviation scores decreased in both groups, the height decline was greater in the DSA group between one and two years from the start of TKI therapy. In this study, dasatinib achieved faster and higher molecular responses with an acceptable safety profile. Further follow-up is necessary to assess the long-term outcomes of TKI treatment in children.<\/jats:p>","DOI":"10.3390\/cancers15153862","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T01:48:50Z","timestamp":1690768130000},"page":"3862","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Front-Line Tyrosine Kinase Inhibitors in Pediatric Chronic Myeloid Leukemia: A Study on Efficacy and Safety"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7970-1691","authenticated-orcid":false,"given":"Jae Won","family":"Yoo","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suejung","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1108-2788","authenticated-orcid":false,"given":"Moon Bae","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongkoo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-0287","authenticated-orcid":false,"given":"Jae Wook","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8632-0168","authenticated-orcid":false,"given":"Myungshin","family":"Kim","sequence":"additional","affiliation":[{"name":"Catholic Genetic Laboratory Center, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"},{"name":"Department of Laboratory Medicine, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4855-390X","authenticated-orcid":false,"given":"Nack-Gyun","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul St. Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,29]]},"reference":[{"key":"ref_1","unstructured":"Howlader, N.N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2020). SEER Cancer Statistics Review, 1975\u20132017."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e27827","DOI":"10.1002\/pbc.27827","article-title":"Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children\u2019s Oncology Group CML Working Group","volume":"66","author":"Athale","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood.2018882233","article-title":"How I treat chronic myeloid leukemia in children and adolescents","volume":"133","author":"Hijiya","year":"2019","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: Results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"key":"ref_8","unstructured":"Bristol Myers Squibb (2013). Sprycel (Dasatinib) Prescribing Information, Bristol-Myers Squibb Company."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/s41375-020-0805-1","article-title":"Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: The DASCERN randomized study","volume":"34","author":"Cortes","year":"2020","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","article-title":"Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: Results from a phase II trial","volume":"36","author":"Gore","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"11","author":"Caldemeyer","year":"2016","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2012.067447","article-title":"Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty","volume":"98","author":"Giona","year":"2013","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/pbc.26028","article-title":"Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia","volume":"63","author":"Samis","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.HS9.0000559876.36369.09","article-title":"Growth rate and endocrine effects of dasatinib therapy observed in a retrospective analysis of a phase 2 clinical trial for pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP)","volume":"3","author":"Patterson","year":"2019","journal-title":"HemaSphere"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00432-014-1746-8","article-title":"Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase","volume":"140","author":"Lauseker","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3345\/kjp.2018.61.5.135","article-title":"The 2017 Korean National Growth Charts for children and adolescents: Development, improvement, and prospects","volume":"61","author":"Kim","year":"2018","journal-title":"Korean J. Pediatr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1122714","DOI":"10.3389\/fonc.2023.1122714","article-title":"Case report: First report of isolated central nervous system lymphoblastic crisis in a child with chronic myeloid leukemia on dasatinib therapy","volume":"13","author":"Jo","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"928136","DOI":"10.3389\/fped.2022.928136","article-title":"Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia","volume":"10","author":"Kim","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.2020005514","article-title":"Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia","volume":"137","author":"Shanmuganathan","year":"2021","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/cncr.30639","article-title":"Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study","volume":"123","author":"Perry","year":"2017","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable bcr-abl1, the criteria for imatinib discontinuation in patients with cml","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.21873\/anticanres.14538","article-title":"Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients","volume":"40","author":"Markovic","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","article-title":"Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): A single-arm, multicentre, phase 2 trial","volume":"7","author":"Kimura","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Millot, F., Suttorp, M., Ragot, S., Leverger, G., Dalle, J.H., Thomas, C., Cheikh, N., Nelken, B., Poiree, M., and Plat, G. (2021). Discontinuation of imatinib in children with chronic myeloid leukemia: A study from the International Registry of Childhood CML. Cancers, 13.","DOI":"10.3390\/cancers13164102"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e29699","DOI":"10.1002\/pbc.29699","article-title":"Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia","volume":"69","author":"Shima","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3390\/hemato3040048","article-title":"Update in childhood chronic myeloid leukemia","volume":"3","author":"Giona","year":"2022","journal-title":"Hemato"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","article-title":"Growth deceleration in children treated with imatinib for chronic myeloid leukaemia","volume":"50","author":"Millot","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/pbc.24121","article-title":"Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia","volume":"59","author":"Rastogi","year":"2012","journal-title":"Pediatr. Blood Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/3862\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:22:05Z","timestamp":1760127725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/3862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,29]]},"references-count":33,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cancers15153862"],"URL":"https:\/\/doi.org\/10.3390\/cancers15153862","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,29]]}}}